Consumer wearable devices for evaluation of heart rate control using digoxin versus beta-blockers: the RATE-AF randomized trial

• Published in: Nature medicine Vol. 30; no. 7; pp. 2030 - 2036
• Main Authors: Gill, Simrat K., Barsky, Andrey, Guan, Xin, Bunting, Karina V., Karwath, Andreas, Tica, Otilia, Stanbury, Mary, Haynes, Sandra, Folarin, Amos, Dobson, Richard, Kurps, Julia, Asselbergs, Folkert W., Grobbee, Diederick E., Camm, A. John, Eijkemans, Marinus J. C., Gkoutos, Georgios V., Kotecha, Dipak
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01-07-2024; Nature Publishing Group
• Subjects: 692/699/75/29/1309; 692/700/565/1436; Adrenergic beta-Antagonists - pharmacology; Adrenergic beta-Antagonists - therapeutic use; Aged; Aged, 80 and over; Arrhythmia; Artificial neural networks; Atrial Fibrillation - drug therapy; Atrial Fibrillation - physiopathology; Beta blockers; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cardiac arrhythmia; Congestive heart failure; Digoxin; Digoxin - pharmacology; Digoxin - therapeutic use; Equivalence; Exercise; Female; Fibrillation; Heart failure; Heart Failure - drug therapy; Heart Failure - physiopathology; Heart rate; Heart Rate - drug effects; Humans; Infectious Diseases; Male; Metabolic Diseases; Missing data; Molecular Medicine; Neural networks; Neurosciences; Patients; Physical activity; Regression coefficients; Smartphone; Statistical analysis; Technology assessment; Wearable computers; Wearable Electronic Devices; Wearable technology; Wrist
• ISSN: 1078-8956; 1546-170X; 1546-170X
• DOI: 10.1038/s41591-024-03094-4

Consumer-grade wearable technology has the potential to support clinical research and patient management. Here, we report results from the RATE-AF trial wearables study, which was designed to compare heart rate in older, multimorbid patients with permanent atrial fibrillation and heart failure who were randomized to treatment with either digoxin or beta-blockers. Heart rate (
n
 = 143,379,796) and physical activity (
n
 = 23,704,307) intervals were obtained from 53 participants (mean age 75.6 years (s.d. 8.4), 40% women) using a wrist-worn wearable linked to a smartphone for 20 weeks. Heart rates in participants treated with digoxin versus beta-blockers were not significantly different (regression coefficient 1.22 (95% confidence interval (CI) −2.82 to 5.27;
P
 = 0.55); adjusted 0.66 (95% CI −3.45 to 4.77;
P
 = 0.75)). No difference in heart rate was observed between the two groups of patients after accounting for physical activity (
P
 = 0.74) or patients with high activity levels (≥30,000 steps per week;
P
 = 0.97). Using a convolutional neural network designed to account for missing data, we found that wearable device data could predict New York Heart Association functional class 5 months after baseline assessment similarly to standard clinical measures of electrocardiographic heart rate and 6-minute walk test (F1 score 0.56 (95% CI 0.41 to 0.70) versus 0.55 (95% CI 0.41 to 0.68);
P
 = 0.88 for comparison). The results of this study indicate that digoxin and beta-blockers have equivalent effects on heart rate in atrial fibrillation at rest and on exertion, and suggest that dynamic monitoring of individuals with arrhythmia using wearable technology could be an alternative to in-person assessment. ClinicalTrials.gov identifier:
NCT02391337
.
In a substudy of the RATE-AF trial, which compared heart rate control therapy using digoxin or the beta-blocker bisoprolol, heart rate and physical activity data collected using a wearable device showed equivalent heart rate control by the two drugs and could be used to predict future heart failure functional class as well as standard clinical measurements.